As a "new favorite" for blood sugar control among patients with Type 2 diabetes, Semaglutide injection has seen a significant reduction in treatment costs following its inclusion in the national medical insurance program; however, reimbursement is contingent upon meeting specific criteria.
Core Reimbursement Criteria: Strictly Limited to Specific Diabetes Treatment Scenarios
It applies exclusively to adult patients with Type 2 diabetes under two specific conditions:
1. When blood sugar control remains inadequate despite combined treatment involving diet, exercise, and/or other anti-diabetic medications (such as Metformin);
2. For patients with Type 2 diabetes who also have concomitant cardiovascular disease, for the purpose of preventing cardiovascular events.
Use solely for weight loss purposes falls outside the scope of medical insurance coverage, even if the drug's official product labeling includes weight reduction as an approved indication.
Reimbursement Rates: Significant Regional Variations; "Class B" Drugs Require Initial Co-payment
Taking the 3mg dosage strength as an example:
* Beijing: 500 RMB per box; after a 30% co-payment, 70% is reimbursed, resulting in an actual out-of-pocket cost of approximately 195 RMB.
* Shanghai: 480 RMB per box; after a 25% co-payment, 75% is reimbursed, resulting in an actual out-of-pocket cost of approximately 156 RMB.
* Chengdu: 460 RMB per box; after a 20% co-payment, 80% is reimbursed, resulting in an actual out-of-pocket cost of approximately 110 RMB.
Under new policies effective in 2025, the maximum co-payment ratio for "Class B" drugs will be capped at 5%, thereby continuing to alleviate the financial burden on patients with chronic diseases.
Reimbursement Operational Guide: Three Steps to Secure Cost Reductions
1. Eligibility Verification: Confirm your eligibility for drug reimbursement via the "National Medical Insurance Service Platform" mini-program.
2. Chronic Disease Certification: Bring your medical records to a local Medical Insurance Center to apply for "Outpatient Chronic and Special Disease" status. Once approved, your reimbursement rate will increase by 15%–20%, potentially saving you thousands of RMB annually.
* If your application is rejected, you may file an appeal via the 12345 hotline or the official website of the National Medical Insurance Administration. You may need to submit supplementary materials, such as community blood pressure monitoring records, medical records from a Class 3A hospital, and pharmacy receipts. In Hanshou, Hunan-a pilot region-designated review windows at participating pharmacies are available to assist patients with filing online appeals.
3. Cross-Provincial Medical Care: Register your cross-provincial medical care needs via the official National Medical Insurance App. Select a hospital that supports cross-provincial direct settlement to enable direct payment using your digital Medical Insurance Code.
Pitfall Guide: Three Scenarios Where Reimbursement Is Denied
Tablets are not covered by medical insurance and must be paid for entirely out-of-pocket;
Purchases made at standard pharmacies are ineligible for reimbursement (with the exception of "Dual-Channel" pharmacies);
Off-label use (e.g., a doctor prescribing medication for weight loss) results in immediate denial of payment.
2025 Policy Benefits: More Affordable Medication for Chronic Diseases
Cities such as Shanghai and Guangzhou have added 32 new medications to their reimbursement lists, resulting in a 70% reduction in the patient's out-of-pocket share. In Miluo, Hunan, diabetic patients who purchase medication through community hospitals can save 900 yuan annually compared to purchasing from tertiary hospitals (based on an estimated annual treatment cost of 6,000 yuan).
Recommendation: Prioritize obtaining prescriptions from community hospitals (where the reimbursement rate is 15% higher) and stay informed about the annual updates to the medical insurance formulary.
Summary: Compliant Medication Use + Precise Reimbursement = Potential Annual Savings of Over 10,000 Yuan
Strictly adhering to approved indications for diabetes treatment-along with mastering reimbursement lookup tools, obtaining chronic disease certification in advance, and selecting designated medical institutions-are the keys to maximizing reimbursement efficiency. With policies continuing to be optimized in 2025, adhering to standardized medication protocols and compliant procedures will further alleviate the financial burden associated with long-term medical treatment.